Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
150 studies found for:    KRAS OR EGFR OR ALK OR PIK3CA OR HER2 OR BRAF OR ROS OR RET OR NRAS OR MET | lung cancer | Studies received from 01/01/2013 to 01/01/2014
Show Display Options
Rank Status Study
1 Recruiting A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
Conditions: Lung Cancer;   Non-Small Cell Lung Cancer
Interventions: Drug: MEK162;   Drug: Erlotinib
2 Active, not recruiting Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer;   Lung Cancer
Intervention: Drug: defactinib (VS-6063)
3 Recruiting A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib and Erlotinib, in Non-small Cell Lung Cancer(NSCLC)Treatment
Conditions: Non-small Cell Lung Cancer (NSCLC);;   EGFR-TKI Resistant Mutation;;   EGFR-TKI Sensitizing Mutation;;   Germline Mutations
Intervention:
4 Active, not recruiting Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Ipilimumab;   Drug: Erlotinib;   Drug: Crizotinib;   Drug: Nivolumab
5 Completed Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer
Conditions: Anaplastic Lymphoma Kinase (ALK);   Non-small Cell Lung Cancer
Interventions: Drug: LDK378;   Drug: AUY922
6 Recruiting A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Condition: ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Interventions: Drug: PF-06463922;   Drug: Crizotinib
7 Active, not recruiting Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
Condition: HER2-mutant Non-Small Cell Lung Cancer
Interventions: Drug: neratinib;   Drug: temsirolimus
8 Recruiting Gefitinib With or Without Pemetrexed/Cisplatin in Brain Metastases From Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Brain Metastases;   EGFR Mutation
Interventions: Drug: Gefitinib and Pemetrexed/cisplatin;   Drug: Gefitinib mono-therapy
9 Unknown  Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer
Condition: Non-Small Cell Lung Cancer
Intervention:
10 Recruiting Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dasatinib - 1A;   Drug: Afatinib - 1A;   Drug: Dasatinib - 1B;   Drug: Afatinib - 1B
11 Active, not recruiting LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: LDK378;   Drug: Pemetrexed + cisplatin or pemetrexed + carboplatin
12 Completed A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
Condition: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib;   Drug: onartuzumab;   Drug: placebo
13 Active, not recruiting
Has Results
A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment
Condition: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva];   Drug: RO5452802
14 Recruiting Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer
Conditions: Non Squamous Non-small Cell Lung Cancer;   Brain Metastases;   Bevacizumab
Interventions: Drug: Pemetrexed/cisplatin;   Drug: Bevacizumab and Pemetrexed/cisplatin
15 Recruiting Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer
Condition: EGFR-Mutant Lung Cancer
Intervention: Drug: erlotinib
16 Recruiting MSC2156119J With Gefitinib in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer
Interventions: Drug: MSC2156119J;   Drug: Gefitinib;   Drug: Pemetrexed;   Drug: Cisplatin
17 Active, not recruiting Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Bortezomib;   Drug: Acyclovir
18 Completed Retrospective Study in a NSCLC M+ p
Condition: EGFR Mutated Non-small Cell Lung Cancer Patients
Intervention:
19 Recruiting Analysis of Plasma Tumor DNA in Lung Cancer Patients
Condition: Non Small Cell Lung Cancer Patients
Intervention:
20 Recruiting Vandetanib in Advanced NSCLC With RET Rearrangement
Condition: Non Small Cell Lung Cancer
Intervention: Drug: Vandetanib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years